

MARTHA C. NASON, PH.D.

Biostatistics Research Branch, NIAID, NIH
5601 Fishers Lane, Rockville, MD 20852
240-669-5251
mnason@niaid.nih.gov

PROFESSIONAL EXPERIENCE:

Mathematical Statistician, Division of Clinical Research, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD (Sept 7 2003 – Present)

- Participate in designing phase 3 clinical trials for assessing the safety and efficacy of Covid-19 vaccines, including as a member of the protocol team for AstraZenica and Novavax vaccine trials; share information and discuss best-practices with other members of US Government's Operation Warp Speed/ Countermeasures Acceleration Group.
- Provide statistical and mathematical leadership and expert consultation to scientists on design and analysis of pre-clinical and clinical research projects.
- Advise NIAID leadership and other senior officials on interpretation of ongoing studies or results, especially those with complex statistical issues; initiating new statistical methods or major revisions to current statistical methodology.
- Act as liaison between pharmaceutical companies, NIH, and independent experts as Executive Secretary of Data Safety Monitoring Boards for HIV Vaccines and Covid-19 preventive Antibodies.
- Support the NIH Covid-19 Treatment Guidelines Panel on evaluation of published research and crafting of recommendations
- Lead and/or co-teach multiple workshops on Biostatistics, Clinical Trial Design, Protocol and Manuscript development to collaborating researchers in international settings to further develop clinical trial capacity. Locations have included Indonesia, Mali, Uganda, South Africa, and Rwanda.
- Develop and evaluate new statistical methodologies for a wide range of research projects to ensure that conclusions and statistical results are scientifically sound, relevant, valid and reliable. Provide oversight or prepare original manuscripts describing novel mathematical statistical techniques developed.

Adjunct Faculty, Johns Hopkins University, Advanced Academic Programs, Rockville, MD (2008 – Present).

- Teach 1-2 sections of an introductory Biostatistics class to graduate students

EDUCATION:

Ph.D. Department of Biostatistics, University of Washington, Seattle, WA (2003)
M.S. Department of Biostatistics, University of Washington, Seattle, WA (1999)
B.S. Department of Psychology, University of Washington, Seattle, WA (1996)
Brown University, Providence, RI (1990 – 1992)

RESEARCH INTERESTS:

Statistical issues in Infectious Diseases, Epidemics, Vaccines, Therapeutics and Diagnostics; Design and Analysis of Clinical Trials, especially for Vaccines; Data and Safety Monitoring Boards; International Biostatistical Capacity Building; Global Health; Statistical Consulting; Graphics & Visualization of complex models; Statistics Education

SELECTED PROFESSIONAL SERVICE:

Executive Secretary, NIAID Preventive Antibodies for COVID-19 Data Safety Monitoring Board (July 2020-Present) and NIAID Vaccine Data Safety Monitoring Board (2011-Present)

Member:

- Operation Warp Speed / CoVPN Statistics Group (July 2020-Present)
- Data Safety Monitoring Board for Immunotherapeutics for HIV Disease, American Gene Therapeutics (2017 – 2019)
- Health Organization Blueprint working group on Vaccine Trial Designs during Public Health Emergencies (2016 - Present)
- NIAID Institutional Review Board (IRB) (2014-2019)
- FDA Arthritis Advisory Committee (2019- present)
- Data Monitoring Committee for Trial of Ciproflaxin for Plague in Uganda, CDC (2011-2016)
- Data Monitoring Committee, Division of Allergy, Immunology and Transplantation, NIAID, NIH (2011-Present)

Reviewer: NEJM; Nature; Nature Medicine; Trials; Journal of Immunological Methods; BMC Bioinformatics; Cytometry; Statistics in Medicine; Vaccine; PLOS ONE (2007 - Present)

AWARDS AND HONORS:

NIH Director's Award (2021, 2013)

NIH Merit Award (2020 (x2), 2019 (x2), 2010)

Secretary's Award for Distinguished Service, Department of Health and Human Services (2016)

Graduate Research Fellowship, National Science Foundation (1997 – 2000)

SELECTED PUBLICATIONS:

1. Gilbert, P.B., Montefiori, D.C., McDermott, A.B., Fong, Y., Benkeser, D., Deng, W., Zhou, H., Houchens, C.R., Martins, K., Jayashankar, L., Castellino, F., Flach, B., Lin, B.C., O'Connell, S., McDanal, C., Eaton, A., Sarzotti-Kelsoe, M., Lu, Y., Yu, C., Borate, B., van der Laan, L.W.P., Hejazi, N.S., Huynh, C., Miller, J., El Sahly, H.M., Baden, L.R., Baron, M., De La Cruz, L., Gay, C., Kalams, S., Kelley, C.F., Andrasik, M.P., Kublin, J.G., Corey, L., Neuzil, K.M., Carpp, L.N., Pajon, R., Follmann, D., Donis, R.O., Koup, R.A., Immune Assays Team section, s., Moderna, I.T.s.s., Coronavirus Vaccine Prevention Network /Coronavirus Efficacy Team section, s., and United States Government /Co, V.P.N.B.T.s.s., **Immune correlates analysis of the mRNA-1273 COVID-19 vaccine efficacy clinical trial.** *Science*, 2022.
2. Gagne, M., Corbett, K.S., Flynn, B.J., Foulds, K.E., Wagner, D.A., Andrew, S.F., Todd, J.M., Honeycutt, C.C., McCormick, L., Nurmukhambetova, S.T., Davis-Gardner, M.E., Pessaint, L., Bock, K.W., Nagata, B.M., Minai, M., Werner, A.P., Moliva, J.I., Tucker, C., Lorang, C.G., Zhao, B., McCarthy, E., Cook, A., Dodson, A., Teng, I.T., Mudvari, P., Roberts-Torres, J., Laboune, F., Wang, L., Goode, A., Kar, S., Boyoglu-Barnum, S., Yang, E.S., Shi, W., Ploquin, A., Doria-Rose, N., Carfi, A., Mascola, J.R., Boritz, E.A., Edwards, D.K., Andersen, H., Lewis, M.G., Suthar, M.S., Graham, B.S., Roederer, M., Moore, I.N., Nason, M.C., Sullivan, N.J., Douek, D.C., and Seder, R.A., **Protection from SARS-CoV-2 Delta one year after mRNA-1273 vaccination in rhesus macaques coincides with anamnestic antibody response in the lung.** *Cell*, 2022.

3. Falsey, A.R., Sobieszczyk, M.E., Hirsch, I., Sproule, S., Robb, M.L., Corey, L., Neuzil, K.M., Hahn, W., Hunt, J., Mulligan, M.J., McEvoy, C., DeJesus, E., Hassman, M., Little, S.J., Pahud, B.A., Durbin, A., Pickrell, P., Daar, E.S., Bush, L., Solis, J., Carr, Q.O., Oyedele, T., Buchbinder, S., Cowden, J., Vargas, S.L., Benavides, A.G., Call, R., Keefer, M.C., Kirkpatrick, B.D., Pullman, J., Tong, T., Isaacs, M.B., Benkeser, D., Janes, H.E., Nason, M.C., Green, J.A., Kelly, E.J., Maaske, J., Mueller, N., Shoemaker, K., Takas, T., Marshall, R.P., Pangalos, M.N., Villafana, T., Gonzalez-Lopez, A., and AstraZeneca, A.Z.D.C.S.G., **Phase 3 Safety and Efficacy of AZD1222 (ChAdOx1 nCoV-19) Covid-19 Vaccine.** *N Engl J Med*, 2021.

4. Pegu, A., O'Connell, S.E., Schmidt, S.D., O'Dell, S., Talana, C.A., Lai, L., Albert, J., Anderson, E., Bennett, H., Corbett, K.S., Flach, B., Jackson, L., Leav, B., Ledgerwood, J.E., Luke, C.J., Makowski, M., Nason, M.C., Roberts, P.C., Roederer, M., Rebolledo, P.A., Rostad, C.A., Roupshael, N.G., Shi, W., Wang, L., Widge, A.T., Yang, E.S., m, R.N.A.S.G.s.s., Beigel, J.H., Graham, B.S., Mascola, J.R., Suthar, M.S., McDermott, A.B., Doria-Rose, N.A., Arega, J., Beigel, J.H., Buchanan, W., Elsayf, M., Hoang, B., Lampl, R., Kolhekar, A., Koo, H., Luke, C., Makhene, M., Nayak, S., Pikaart-Tautges, R., Roberts, P.C., Russell, J., Sindall, E., Albert, J., Kunwar, P., Makowski, M., Anderson, E.J., Bechnak, A., Bower, M., Camacho-Gonzalez, A.F., Collins, M., Drobeniuc, A., Edara, V.V., Edupuganti, S., Floyd, K., Gibson, T., Ackerley, C.M.G., Johnson, B., Kamidani, S., Kao, C., Kelley, C., Lai, L., Macenczak, H., McCullough, M.P., Peters, E., Phadke, V.K., Rebolledo, P.A., Rostad, C.A., Roupshael, N., Scherer, E., Sherman, A., Stephens, K., Suthar, M.S., Teherani, M., Traenkner, J., Winston, J., Yildirim, I., Barr, L., Benoit, J., Carste, B., Choe, J., Dunstan, M., Erolin, R., Ffitch, J., Fields, C., Jackson, L.A., Kiniry, E., Lasicka, S., Lee, S., Nguyen, M., Pimienta, S., Suyehira, J., Witte, M., Bennett, H., Altaras, N.E., Carfi, A., Hurley, M., Leav, B., Pajon, R., Sun, W., Zaks, T., Coler, R.N., Larsen, S.E., Neuzil, K.M., Lindesmith, L.C., Martinez, D.R., Munt, J., Mallory, M., Edwards, C., Baric, R.S., Berkowitz, N.M., Boritz, E.A., Carlton, K., Corbett, K.S., Costner, P., Creanga, A., Doria-Rose, N.A., Douek, D.C., Flach, B., Gaudinski, M., Gordon, I., Graham, B.S., Holman, L., Ledgerwood, J.E., Leung, K., Lin, B.C., Louder, M.K., Mascola, J.R., McDermott, A.B., Morabito, K.M., Novik, L., O'Connell, S., O'Dell, S., Padilla, M., Pegu, A., Schmidt, S.D., Shi, W., Swanson, P.A., 2nd, Talana, C.A., Wang, L., Widge, A.T., Yang, E.S., Zhang, Y., Chappell, J.D., Denison, M.R., Hughes, T., Lu, X., Pruijssers, A.J., Stevens, L.J., Posavad, C.M., Gale, M., Jr., Menachery, V. and Shi, P.Y., **Durability of mRNA-1273 vaccine-induced antibodies against SARS-CoV-2 variants.** *Science*, 2021.

5. Corbett, K.S., Nason, M.C., Flach, B., Gagne, M., O'Connell, S., Johnston, T.S., Shah, S.N., Edara, V.V., Floyd, K., Lai, L., McDanal, C., Francica, J.R., Flynn, B., Wu, K., Choi, A., Koch, M., Abiona, O.M., Werner, A.P., Moliva, J.I., Andrew, S.F., Donaldson, M.M., Fintzi, J., Flebbe, D.R., Lamb, E., Noe, A.T., Nurmukhambetova, S.T., Provost, S.J., Cook, A., Dodson, A., Faudree, A., Greenhouse, J., Kar, S., Pessaint, L., Porto, M., Steingrebe, K., Valentin, D., Zouantcha, S., Bock, K.W., Minai, M., Nagata, B.M., van de Wetering, R., Boyoglu-Barnum, S., Leung, K., Shi, W., Yang, E.S., Zhang, Y., Todd, J.M., Wang, L., Alvarado, G.S., Andersen, H., Foulds, K.E., Edwards, D.K., Mascola, J.R., Moore, I.N., Lewis, M.G., Carfi, A., Montefiori, D., Suthar, M.S., McDermott, A., Roederer, M., Sullivan, N.J., Douek, D.C., Graham, B.S., and Seder, R.A., **Immune correlates of protection by mRNA-1273 vaccine against SARS-CoV-2 in nonhuman primates.** *Science*, 2021.

6. Ortega-Villa, A.M., Nason, M.C., and Follmann, D., **The mechanistic analysis of founder virus data in challenge models.** *Stat Med*, 2021.

7. Ciocanea-Teodorescu, I., Nason, M., Sjolander, A., and Gabriel, E.E., **Adjustment for Disease Severity in the Test-Negative Study Design.** *Am J Epidemiol*, 2021.

8. Corbett, K.S., Gagne, M., Wagner, D.A., S, O.C., Narpala, S.R., Flebbe, D.R., Andrew, S.F., Davis, R.L., Flynn, B., Johnston, T.S., Stringham, C.D., Lai, L., Valentin, D., Van Ry, A., Flinchbaugh, Z., Werner, A.P., Moliva, J.I., Sriparna, M., O'Dell, S., Schmidt, S.D., Tucker, C., Choi, A., Koch, M., Bock, K.W., Minai, M., Nagata, B.M., Alvarado, G.S., Henry, A.R., Laboune, F., Schramm, C.A., Zhang, Y., Yang, E.S., Wang, L., Choe, M., Boyoglu-Barnum, S., Wei, S., Lamb, E., Nurmukhambetova, S.T., Provost, S.J., Donaldson, M.M., Marquez, J., Todd, J.M., Cook, A., Dodson, A., Pekosz, A., Boritz, E., Ploquin, A., Doria-Rose, N., Pessaint, L., Andersen, H., Foulds, K.E., Misasi, J., Wu, K., Carfi, A., Nason, M.C., Mascola, J., Moore, I.N., Edwards, D.K., Lewis, M.G., Suthar, M.S., Roederer, M., McDermott, A., Douek, D.C., Sullivan, N.J., Graham, B.S., and Seder, R.A., **Protection against SARS-CoV-2 beta variant in mRNA-1273 vaccine-boosted nonhuman primates.** *Science*, 2021.

9. Ruckwardt, T.J., Morabito, K.M., Phung, E., Crank, M.C., Costner, P.J., Holman, L.A., Chang, L.A., Hickman, S.P., Berkowitz, N.M., Gordon, I.J., Yamshchikov, G.V., Gaudinski, M.R., Lin, B., Bailer, R., Chen, M., Ortega-Villa, A.M., Nguyen, T., Kumar, A., Schwartz, R.M., Kueltzo, L.A., Stein, J.A., Carlton, K., Gall, J.G., Nason, M.C., Mascola, J.R., Chen, G., Graham, B.S., and team, V.R.C.S., **Safety, tolerability, and immunogenicity of the respiratory syncytial virus prefusion F subunit vaccine DS-Cav1: a phase 1, randomised, open-label, dose-escalation clinical trial.** *Lancet Respir Med*, 2021.
10. Corbett, K.S., Werner, A.P., Connell, S.O., Gagne, M., Lai, L., Moliva, J.I., Flynn, B., Choi, A., Koch, M., Foulds, K.E., Andrew, S.F., Flebbe, D.R., Lamb, E., Nurmukhambetova, S.T., Provost, S.J., Bock, K.W., Minai, M., Nagata, B.M., Ry, A.V., Flinchbaugh, Z., Johnston, T.S., Mokhtari, E.B., Mudvari, P., Henry, A.R., Laboune, F., Chang, B., Porto, M., Wear, J., Alvarado, G.S., Boyoglu-Barnum, S., Todd, J.M., Bart, B., Cook, A., Dodson, A., Pessaint, L., Steingrebe, K., Elbashir, S., Sriparna, M., Pekosz, A., Andersen, H., Wu, K., Edwards, D.K., Kar, S., Lewis, M.G., Boritz, E., Moore, I.N., Carfi, A., Suthar, M.S., McDermott, A., Roederer, M., Nason, M.C., Sullivan, N.J., Douek, D.C., Graham, B.S., and Seder, R.A., **mRNA-1273 protects against SARS-CoV-2 beta infection in nonhuman primates.** *Nat Immunol*, 2021.
11. Corbett, K.S., Werner, A.P., S, O.C., Gagne, M., Lai, L., Moliva, J.I., Flynn, B., Choi, A., Koch, M., Foulds, K.E., Andrew, S.F., Flebbe, D.R., Lamb, E., Nurmukhambetova, S.T., Provost, S.J., Bock, K.W., Minai, M., Nagata, B.M., Van Ry, A., Flinchbaugh, Z., Johnston, T.S., Mokhtari, E.B., Mudvari, P., Henry, A.R., Laboune, F., Chang, B., Porto, M., Wear, J., Alvarado, G.S., Boyoglu-Barnum, S., Todd, J.M., Bart, B., Cook, A., Dodson, A., Pessaint, L., Steingrebe, K., Elbashir, S., Andersen, H., Wu, K., Edwards, D.K., Kar, S., Lewis, M.G., Bortiz, E., Moore, I.N., Carfi, A., Suthar, M.S., McDermott, A., Roederer, M., Nason, M.C., Sullivan, N.J., Douek, D.C., Graham, B.S., and Seder, R.A., **Evaluation of mRNA-1273 against SARS-CoV-2 B.1.351 Infection in Nonhuman Primates.** *bioRxiv*, 2021.
12. Parta, M., Cole, K., Avila, D., Duncan, L., Baird, K., Schuver, B.B., Wilder, J., Palmer, C., Daub, J., Hsu, A.P., Zerbe, C.S., Marciano, B.E., Cuellar-Rodriguez, J.M., Bauer, T.R., Nason, M., Calvo, K.R., Merideth, M., Stratton, P., DeCherney, A., Shah, N.N., Holland, S.M., and Hickstein, D.D., **Hematopoietic Cell Transplantation and Outcomes Related to Human Papillomavirus Disease in GATA2 Deficiency.** *Transplant Cell Ther*, 2021.
13. Higgs, E.S., Gayedyu-Dennis, D., Fisher, W., Nason, M., Reilly, C., Beavogui, A.H., Aboulhab, J., Nordwall, J., Lobbo, P., Wachekwa, I., Cao, H., Cihlar, T., Hensley, L., and Lane, H.C., **PREVAIL IV: A Randomized, Double-Blind, Two-Phase, Phase 2 Trial of Remdesivir versus Placebo for Reduction of Ebola Virus RNA in the Semen of Male Survivors.** *Clin Infect Dis*, 2021.
14. Breglio, K.F., Vinhaes, C.L., Arriaga, M.B., Nason, M., Roby, G., Adelsberger, J., Andrade, B.B., Sheikh, V., and Sereti, I., **Clinical and Immunologic Predictors of Mycobacterium avium Complex Immune Reconstitution Inflammatory Syndrome in a Contemporary Cohort of Patients With Human Immunodeficiency Virus.** *J Infect Dis*, 2021.
15. Fleming, T.R., Krause, P.R., Nason, M., Longini, I.M., and Henao-Restrepo, A.M., **COVID-19 vaccine trials: The use of active controls and non-inferiority studies.** *Clin Trials*, 2021.
16. Mwakngwe-Omari, A., Healy, S.A., Lane, J., Cook, D.M., Kalhori, S., Wyatt, C., Kolluri, A., Marte-Salcedo, O., Imeru, A., Nason, M., Ding, L.K., Decederfelt, H., Duan, J., Neal, J., Raiten, J., Lee, G., Hume, J.C.C., Jeon, J.E., Ikpeama, I., Kc, N., Chakravarty, S., Murshedkar, T., Church, L.W.P., Manoj, A., Gunasekera, A., Anderson, C., Murphy, S.C., March, S., Bhatia, S.N., James, E.R., Billingsley, P.F., Sim, B.K.L., Richie, T.L., Zaidi, I., Hoffman, S.L., and Duffy, P.E., **Two chemoattenuated PfSPZ malaria vaccines induce sterile hepatic immunity.** *Nature*, 2021.
17. Evaluation, W.H.O.A.H.E.G.o.t.N.S.f.C.-V., Krause, P.R., Fleming, T.R., Longini, I.M., Peto, R., Beral, V., Bhargava, B., Cravioto, A., Cramer, J.P., Ellenberg, S.S., Figueroa, J.P., Halloran, E., Henao-Restrepo, A.M., Ryan, M.J., Levine, M.M., Nason, M., Nohynek, H.M., Plotkin, S., Rees, H., Singh, J.A., and Swaminathan, S., **Placebo-Controlled Trials of Covid-19 Vaccines - Why We Still Need Them.** *N Engl J Med*, 2021.
18. Mehrotra, D.V., Janes, H.E., Fleming, T.R., Annunziato, P.W., Neuzil, K.M., Carpp, L.N., Benkeser, D., Brown, E.R., Carone, M., Cho, I., Donnell, D., Fay, M.P., Fong, Y., Han, S., Hirsch, I., Huang, Y., Huang, Y., Hyrien, O., Juraska,

- M., Luedtke, A., Nason, M., Vandebosch, A., Zhou, H., Cohen, M.S., Corey, L., Hartzel, J., Follmann, D., and Gilbert, P.B., **Clinical Endpoints for Evaluating Efficacy in COVID-19 Vaccine Trials.** *Ann Intern Med*, 2021.
19. Corbett, K.S., Gagne, M., Wagner, D.A., Connell, S.O., Narpala, S.R., Flebbe, D.R., Andrew, S.F., Davis, R.L., Flynn, B., Johnston, T.S., Stringham, C., Lai, L., Valentin, D., Van Ry, A., Flinchbaugh, Z., Werner, A.P., Moliva, J.I., Sriparna, M., O'Dell, S., Schmidt, S.D., Tucker, C., Choi, A., Koch, M., Bock, K.W., Minai, M., Nagata, B.M., Alvarado, G.S., Henry, A.R., Laboune, F., Schramm, C.A., Zhang, Y., Wang, L., Choe, M., Boyoglu-Barnum, S., Shi, W., Lamb, E., Nurmukhambetova, S.T., Provost, S.J., Donaldson, M.M., Marquez, J., Todd, J.M., Cook, A., Dodson, A., Pekosz, A., Boritz, E., Ploquin, A., Doria-Rose, N., Pessaint, L., Andersen, H., Foulds, K.E., Misasi, J., Wu, K., Carfi, A., Nason, M.C., Mascola, J., Moore, I.N., Edwards, D.K., Lewis, M.G., Suthar, M.S., Roederer, M., McDermott, A., Douek, D.C., Sullivan, N.J., Graham, B.S., and Seder, R.A., **Protection against SARS-CoV-2 Beta Variant in mRNA-1273 Boosted Nonhuman Primates.** *bioRxiv*, 2021.
 20. Garber, D.A., Guenther, P., Mitchell, J., Ellis, S., Gazumyan, A., Nason, M., Seaman, M.S., McNicholl, J.M., Nussenzweig, M.C., and Heneine, W., **Broadly neutralizing antibody-mediated protection of macaques against repeated intravenous exposures to simian-human immunodeficiency virus.** *AIDS*, 2021.
 21. Kuriakose, S., Singh, K., Pau, A.K., Daar, E., Gandhi, R., Tebas, P., Evans, L., Gulick, R.M., Lane, H.C., Masur, H., Panel, N.C.-T.G., Aberg, J.A., Adimora, A.A., Baker, J., Kreuziger, L.B., Bedimo, R., Belperio, P.S., Cantrill, S.V., Coopersmith, C.M., Davis, S.L., Dzierba, A.L., Gallagher, J.J., Glidden, D.V., Grund, B., Hardy, E.J., Hinkson, C., Hughes, B.L., Johnson, S., Keller, M.J., Kim, A.Y., Lennox, J.L., Levy, M.M., Li, J.Z., Martin, G.S., Naggie, S., Pavia, A.T., Seam, N., Simpson, S.Q., Swindells, S., Tien, P., Waghmare, A.A., Wilson, K.C., Yazdany, J., Zachariah, P., Campbell, D.M., Harrison, C., Burgess, T., Francis, J., Sheikh, V., Uyeki, T.M., Walker, R., Brooks, J.T., Ortiz, L.B., Davey, R.T., Jr., Doepel, L.K., Eisinger, R.W., Han, A., Higgs, E.S., Nason, M.C., Crew, P., Lerner, A.M., Lund, C., and Worthington, C., **Developing Treatment Guidelines During a Pandemic Health Crisis: Lessons Learned From COVID-19.** *Ann Intern Med*, 2021.
 22. Fleming, T.R., Nason, M., Krause, P.R., Longini, I.M., and Henao-Restrepo, A.M., **COVID-19 vaccine trials: The potential for "hybrid" analyses.** *Clin Trials*, 2021.
 23. Follmann, D., Fintzi, J., Fay, M.P., Janes, H.E., Baden, L.R., El Sahly, H.M., Fleming, T.R., Mehrotra, D.V., Carpp, L.N., Juraska, M., Benkeser, D., Donnell, D., Fong, Y., Han, S., Hirsch, I., Huang, Y., Huang, Y., Hyrien, O., Luedtke, A., Carone, M., Nason, M., Vandebosch, A., Zhou, H., Cho, I., Gabriel, E., Kublin, J.G., Cohen, M.S., Corey, L., Gilbert, P.B., and Neuzil, K.M., **A Deferred-Vaccination Design to Assess Durability of COVID-19 Vaccine Effect After the Placebo Group Is Vaccinated.** *Ann Intern Med*, 2021.
 24. Corbett, K.S., Nason, M.C., Flach, B., Gagne, M., S, O.C., Johnston, T.S., Shah, S.N., Edara, V.V., Floyd, K., Lai, L., McDanal, C., Francica, J.R., Flynn, B., Wu, K., Choi, A., Koch, M., Abiona, O.M., Werner, A.P., Alvarado, G.S., Andrew, S.F., Donaldson, M.M., Fintzi, J., Flebbe, D.R., Lamb, E., Noe, A.T., Nurmukhambetova, S.T., Provost, S.J., Cook, A., Dodson, A., Faudree, A., Greenhouse, J., Kar, S., Pessaint, L., Porto, M., Steingrebe, K., Valentin, D., Zouantcha, S., Bock, K.W., Minai, M., Nagata, B.M., Moliva, J.I., van de Wetering, R., Boyoglu-Barnum, S., Leung, K., Shi, W., Yang, E.S., Zhang, Y., Todd, J.M., Wang, L., Andersen, H., Foulds, K.E., Edwards, D.K., Mascola, J.R., Moore, I.N., Lewis, M.G., Carfi, A., Montefiori, D., Suthar, M.S., McDermott, A., Sullivan, N.J., Roederer, M., Douek, D.C., Graham, B.S., and Seder, R.A., **Immune Correlates of Protection by mRNA-1273 Immunization against SARS-CoV-2 Infection in Nonhuman Primates.** *bioRxiv*, 2021.
 25. Hunsberger, S., Ortega-Villa, A.M., Powers, J.H., 3rd, Rincon Leon, H.A., Caballero Sosa, S., Ruiz Hernandez, E., Najera Cancino, J.G., Nason, M., Lombard, K., Sepulveda, J., Guerra de Blas, P.D.C., Ruiz-Palacios, G., Belaunzaran-Zamudio, P.F., and LaRed Zik01 Study, T., **Patterns of signs, symptoms, and laboratory values associated with Zika, dengue, and undefined acute illnesses in a dengue endemic region: Secondary analysis of a prospective cohort study in southern Mexico.** *Int J Infect Dis*, 2020.
 26. Corbett, K.S., Flynn, B., Foulds, K.E., Francica, J.R., Boyoglu-Barnum, S., Werner, A.P., Flach, B., O'Connell, S., Bock, K.W., Minai, M., Nagata, B.M., Andersen, H., Martinez, D.R., Noe, A.T., Douek, N., Donaldson, M.M., Nji, N.N., Alvarado, G.S., Edwards, D.K., Flebbe, D.R., Lamb, E., Doria-Rose, N.A., Lin, B.C., Louder, M.K., O'Dell, S., Schmidt, S.D., Phung, E., Chang, L.A., Yap, C., Todd, J.M., Pessaint, L., Van Ry, A., Browne, S., Greenhouse, J.,

- Putman-Taylor, T., Strasbaugh, A., Campbell, T.A., Cook, A., Dodson, A., Steingrebe, K., Shi, W., Zhang, Y., Abiona, O.M., Wang, L., Pegu, A., Yang, E.S., Leung, K., Zhou, T., Teng, I.T., Widge, A., Gordon, I., Novik, L., Gillespie, R.A., Loomis, R.J., Moliva, J.I., Stewart-Jones, G., Himansu, S., Kong, W.P., Nason, M.C., Morabito, K.M., Ruckwardt, T.J., Ledgerwood, J.E., Gaudinski, M.R., Kwong, P.D., Mascola, J.R., Carfi, A., Lewis, M.G., Baric, R.S., McDermott, A., Moore, I.N., Sullivan, N.J., Roederer, M., Seder, R.A., and Graham, B.S., **Evaluation of the mRNA-1273 Vaccine against SARS-CoV-2 in Nonhuman Primates.** *N Engl J Med*, 2020.
27. Corbett, K.S., Edwards, D.K., Leist, S.R., Abiona, O.M., Boyoglu-Barnum, S., Gillespie, R.A., Himansu, S., Schafer, A., Ziwawo, C.T., DiPiazza, A.T., Dinnon, K.H., Elbashir, S.M., Shaw, C.A., Woods, A., Fritch, E.J., Martinez, D.R., Bock, K.W., Minai, M., Nagata, B.M., Hutchinson, G.B., Wu, K., Henry, C., Bahl, K., Garcia-Dominguez, D., Ma, L., Renzi, I., Kong, W.P., Schmidt, S.D., Wang, L., Zhang, Y., Phung, E., Chang, L.A., Loomis, R.J., Altaras, N.E., Narayanan, E., Metkar, M., Presnyak, V., Liu, C., Louder, M.K., Shi, W., Leung, K., Yang, E.S., West, A., Gully, K.L., Stevens, L.J., Wang, N., Wrapp, D., Doria-Rose, N.A., Stewart-Jones, G., Bennett, H., Alvarado, G.S., Nason, M.C., Ruckwardt, T.J., McLellan, J.S., Denison, M.R., Chappell, J.D., Moore, I.N., Morabito, K.M., Mascola, J.R., Baric, R.S., Carfi, A., and Graham, B.S., **SARS-CoV-2 mRNA vaccine design enabled by prototype pathogen preparedness.** *Nature*, 2020.
28. Finch, C.L., Crozier, I., Lee, J.H., Byrum, R., Cooper, T.K., Liang, J., Sharer, K., Solomon, J., Sayre, P.J., Kocher, G., Bartos, C., Aiosa, N.M., Castro, M., Larson, P.A., Adams, R., Beitzel, B., Di Paola, N., Kugelman, J.R., Kurtz, J.R., Burdette, T., Nason, M.C., Feuerstein, I.M., Palacios, G., St Claire, M.C., Lackemeyer, M.G., Johnson, R.F., Braun, K.M., Ramuta, M.D., Wada, J., Schmaljohn, C.S., Friedrich, T.C., O'Connor, D.H., and Kuhn, J.H., **Characteristic and quantifiable COVID-19-like abnormalities in CT- and PET/CT-imaged lungs of SARS-CoV-2-infected crab-eating macaques (*Macaca fascicularis*).** *bioRxiv*, 2020.
29. Garber, D.A., Adams, D.R., Guenther, P., Mitchell, J., Kelley, K., Schoofs, T., Gazumyan, A., Nason, M., Seaman, M.S., McNicholl, J., Nussenzweig, M.C., and Heneine, W., **Durable protection against repeated penile exposures to simian-human immunodeficiency virus by broadly neutralizing antibodies.** *Nat Commun*, 2020.
30. Corbett, K.S., Edwards, D., Leist, S.R., Abiona, O.M., Boyoglu-Barnum, S., Gillespie, R.A., Himansu, S., Schafer, A., Ziwawo, C.T., DiPiazza, A.T., Dinnon, K.H., Elbashir, S.M., Shaw, C.A., Woods, A., Fritch, E.J., Martinez, D.R., Bock, K.W., Minai, M., Nagata, B.M., Hutchinson, G.B., Bahl, K., Garcia-Dominguez, D., Ma, L., Renzi, I., Kong, W.P., Schmidt, S.D., Wang, L., Zhang, Y., Stevens, L.J., Phung, E., Chang, L.A., Loomis, R.J., Altaras, N.E., Narayanan, E., Metkar, M., Presnyak, V., Liu, C., Louder, M.K., Shi, W., Leung, K., Yang, E.S., West, A., Gully, K.L., Wang, N., Wrapp, D., Doria-Rose, N.A., Stewart-Jones, G., Bennett, H., Nason, M.C., Ruckwardt, T.J., McLellan, J.S., Denison, M.R., Chappell, J.D., Moore, I.N., Morabito, K.M., Mascola, J.R., Baric, R.S., Carfi, A., and Graham, B.S., **SARS-CoV-2 mRNA Vaccine Development Enabled by Prototype Pathogen Preparedness.** *bioRxiv*, 2020.
31. Rosenke, K., Jarvis, M.A., Feldmann, F., Schwarz, B., Okumura, A., Lovaglio, J., Saturday, G., Hanley, P.W., Meade-White, K., Williamson, B.N., Hansen, F., Perez-Perez, L., Leventhal, S., Tang-Huau, T.L., Nason, M., Callison, J., Haddock, E., Scott, D., Sewell, G., Bosio, C.M., Hawman, D., de Wit, E., and Feldmann, H., **Hydroxychloroquine Proves Ineffective in Hamsters and Macaques Infected with SARS-CoV-2.** *bioRxiv*, 2020.
32. Maciejewski, S., Ruckwardt, T.J., Morabito, K.M., Foreman, B.M., Burgomaster, K.E., Gordon, D.N., Pelc, R.S., DeMaso, C.R., Ko, S.Y., Fisher, B.E., Yang, E.S., Nair, D., Foulds, K.E., Todd, J.P., Kong, W.P., Roy, V., Aleshnick, M., Speer, S.D., Bourne, N., Barrett, A.D., Nason, M.C., Roederer, M., Gaudinski, M.R., Chen, G.L., Dowd, K.A., Ledgerwood, J.E., Alter, G., Mascola, J.R., Graham, B.S., and Pierson, T.C., **Distinct neutralizing antibody correlates of protection among related Zika virus vaccines identify a role for antibody quality.** *Sci Transl Med*, 2020.
33. Sereti, I., Sheikh, V., Shaffer, D., Phanuphak, N., Gabriel, E., Wang, J., Nason, M.C., Roby, G., Ngeno, H., Kirui, F., Pau, A., Mican, J.M., Rupert, A., Bishop, R., Agan, B., Chomchey, N., Teeratakulpisarn, N., Tansuphaswadikul, S., Langat, D., Kosgei, J., French, M., Ananworanich, J., and Sawe, F., **Prospective International Study of Incidence and Predictors of Immune Reconstitution Inflammatory Syndrome and Death in People Living With Human Immunodeficiency Virus and Severe Lymphopenia.** *Clin Infect Dis*, 2020.

34. Gouel-Cheron, A., Nason, M., Rupert, A., Sheikh, V., Robby, G., Fahle, G.A., and Sereti, I., **Cardiovascular Biomarker Profile on Antiretroviral Therapy Is Not Influenced by History of an IRIS Event in People With HIV and Suppressed Viremia.** *Open Forum Infect Dis*, 2020.
35. Redd, A.D., Doria-Rose, N.A., Weiner, J.A., Nason, M., Seivers, M., Schmidt, S.D., Laeyendecker, O., Martens, C., Bruno, D., Keele, B.F., Raju, N., Georgiev, I.S., Lamers, S.L., Astemborski, J., Kirk, G.D., Mascola, J.R., Ackerman, M.E., Mehta, S.H., and Quinn, T.C., **Longitudinal Antibody Responses in People Who Inject Drugs Infected With Similar Human Immunodeficiency Virus Strains.** *J Infect Dis*, 2020.
36. Follmann, D., Fintzi, J., Fay, M.P., Janes, H.E., Baden, L., Sahly, H.E., Fleming, T.R., Mehrotra, D.V., Carpp, L.N., Juraska, M., Benkeser, D., Donnell, D., Fong, Y., Han, S., Hirsch, I., Huang, Y., Huang, Y., Hyrien, O., Luedtke, A., Carone, M., Nason, M., Vandebosch, A., Zhou, H., Cho, I., Gabriel, E., Kublin, J.G., Cohen, M.S., Corey, L., Gilbert, P.B., and Neuzil, K.M., **Assessing Durability of Vaccine Effect Following Blinded Crossover in COVID-19 Vaccine Efficacy Trials.** *medRxiv*, 2020.
37. Ssempijja, V., Nason, M., Nakigozi, G., Ndyababo, A., Gray, R., Wawer, M., Chang, L.W., Gabriel, E., Quinn, T.C., Serwadda, D., and Reynolds, S.J., **Adaptive Viral Load Monitoring Frequency to Facilitate Differentiated Care: A Modeling Study From Rakai, Uganda.** *Clin Infect Dis*, 2020.
38. Dean, N.E., Gsell, P.S., Brookmeyer, R., Crawford, F.W., Donnelly, C.A., Ellenberg, S.S., Fleming, T.R., Halloran, M.E., Horby, P., Jaki, T., Krause, P.R., Longini, I.M., Mulangu, S., Muyembe-Tamfum, J.J., Nason, M.C., Smith, P.G., Wang, R., Henao-Restrepo, A.M., and De Gruttola, V., **Creating a Framework for Conducting Randomized Clinical Trials during Disease Outbreaks.** *N Engl J Med*, 2020.
39. Gaudinski, M.R., Coates, E.E., Novik, L., Widge, A., Houser, K.V., Burch, E., Holman, L.A., Gordon, I.J., Chen, G.L., Carter, C., Nason, M., Sitar, S., Yamshchikov, G., Berkowitz, N., Andrews, C., Vazquez, S., Laurencot, C., Misasi, J., Arnold, F., Carlton, K., Lawlor, H., Gall, J., Bailer, R.T., McDermott, A., Capparelli, E., Koup, R.A., Mascola, J.R., Graham, B.S., Sullivan, N.J., Ledgerwood, J.E., and team, V.R.C.S., **Safety, tolerability, pharmacokinetics, and immunogenicity of the therapeutic monoclonal antibody mAb114 targeting Ebola virus glycoprotein (VRC 608): an open-label phase 1 study.** *Lancet*, 2019.
40. Kong, R., Duan, H., Sheng, Z., Xu, K., Acharya, P., Chen, X., Cheng, C., Dingens, A.S., Gorman, J., Sastry, M., Shen, C.H., Zhang, B., Zhou, T., Chuang, G.Y., Chao, C.W., Gu, Y., Jafari, A.J., Louder, M.K., O'Dell, S., Rowshan, A.P., Viox, E.G., Wang, Y., Choi, C.W., Corcoran, M.M., Corrigan, A.R., Dandey, V.P., Eng, E.T., Geng, H., Foulds, K.E., Guo, Y., Kwon, Y.D., Lin, B., Liu, K., Mason, R.D., Nason, M.C., Ohr, T.Y., Ou, L., Rawi, R., Sarfo, E.K., Schon, A., Todd, J.P., Wang, S., Wei, H., Wu, W., Program, N.C.S., Mullikin, J.C., Bailer, R.T., Doria-Rose, N.A., Karlsson Hedestam, G.B., Scorpio, D.G., Overbaugh, J., Bloom, J.D., Carragher, B., Potter, C.S., Shapiro, L., Kwong, P.D., and Mascola, J.R., **Antibody Lineages with Vaccine-Induced Antigen-Binding Hotspots Develop Broad HIV Neutralization.** *Cell*, 2019.
41. Dean, N.E., Gsell, P.S., Brookmeyer, R., De Gruttola, V., Donnelly, C.A., Halloran, M.E., Jasseh, M., Nason, M., Riveros, X., Watson, C.H., Henao-Restrepo, A.M., and Longini, I.M., **Design of vaccine efficacy trials during public health emergencies.** *Sci Transl Med*, 2019.
42. Janes, H., Donnell, D., Gilbert, P.B., Brown, E.R., and Nason, M., **Taking stock of the present and looking ahead: envisioning challenges in the design of future HIV prevention efficacy trials.** *Lancet HIV*, 2019.
43. Crank, M.C., Ruckwardt, T.J., Chen, M., Morabito, K.M., Phung, E., Costner, P.J., Holman, L.A., Hickman, S.P., Berkowitz, N.M., Gordon, I.J., Yamshchikov, G.V., Gaudinski, M.R., Kumar, A., Chang, L.A., Moin, S.M., Hill, J.P., DiPiazza, A.T., Schwartz, R.M., Kueltozo, L., Cooper, J.W., Chen, P., Stein, J.A., Carlton, K., Gall, J.G., Nason, M.C., Kwong, P.D., Chen, G.L., Mascola, J.R., McLellan, J.S., Ledgerwood, J.E., Graham, B.S., and Team, V.R.C.S., **A proof of concept for structure-based vaccine design targeting RSV in humans.** *Science*, 2019.
44. Dorjbal, B., Stinson, J.R., Ma, C.A., Weinreich, M.A., Miraghazadeh, B., Hartberger, J.M., Frey-Jakobs, S., Weidinger, S., Moebus, L., Franke, A., Schaffer, A.A., Bulashevskaya, A., Fuchs, S., Ehl, S., Limaye, S., Arkwright, P.D., Briggs, T.A., Langley, C., Bethune, C., Whyte, A.F., Alachkar, H., Nejentsev, S., DiMaggio, T., Nelson, C.G.,

- Stone, K.D., Nason, M., Brittain, E.H., Oler, A.J., Veltri, D.P., Leahy, T.R., Conlon, N., Poli, M.C., Borzutzky, A., Cohen, J.I., Davis, J., Lambert, M.P., Romberg, N., Sullivan, K.E., Paris, K., Freeman, A.F., Lucas, L., Chandrakasan, S., Savic, S., Hambleton, S., Patel, S.Y., Jordan, M.B., Theos, A., Lebensburger, J., Atkinson, T.P., Torgerson, T.R., Chinn, I.K., Milner, J.D., Grimbacher, B., Cook, M.C., and Snow, A.L., **Hypomorphic caspase activation and recruitment domain 11 (CARD11) mutations associated with diverse immunologic phenotypes with or without atopic disease.** *J Allergy Clin Immunol*, 2019.
45. Brody, I.B., Calcedo, R., Connell, M.J., Carnathan, D.G., Nason, M., Lawson, B.O., Nega, M.T., Boyd, S., Qin, Q., Vanderford, T.H., Wilson, J.M., Wilson, J.M., Silvestri, G., and Betts, M.R., **Susceptibility to SIV Infection After Adenoviral Vaccination in a Low Dose Rhesus Macaque Challenge Model.** *Pathog Immun*, 2019.
46. Gabriel, E.E., Nason, M., Fay, M.P., and Follmann, D.A., **A boundary-optimized rejection region test for the two-sample binomial problem.** *Stat Med*, 2018.
47. Gabriel, E.E., Nason, M., Fay, M.P., and Follmann, D., **Response to letter by Antonio Martin Andres on "A boundary-optimized rejection region test for the two-sample binomial problem".** *Stat Med*, 2018.
48. Le, K., Kopka, S., Chaitt, D., Pierson, J., Nason, M., and Miller, T., **A Survey on Including Risks in the New "Key Information" Section of an Informed Consent Form.** *Clin Res (Alex)*, 2018.
49. Duan, H., Chen, X., Boyington, J.C., Cheng, C., Zhang, Y., Jafari, A.J., Stephens, T., Tsybovsky, Y., Kalyuzhnyi, O., Zhao, P., Menis, S., Nason, M.C., Normandin, E., Mukhamedova, M., DeKosky, B.J., Wells, L., Schief, W.R., Tian, M., Alt, F.W., Kwong, P.D., and Mascola, J.R., **Glycan Masking Focuses Immune Responses to the HIV-1 CD4-Binding Site and Enhances Elicitation of VRC01-Class Precursor Antibodies.** *Immunity*, 2018.
50. Nganou-Makamdop, K., Billingsley, J.M., Yaffe, Z., O'Connor, G., Tharp, G.K., Ransier, A., Laboune, F., Matus-Nicodemos, R., Lerner, A., Gharu, L., Robertson, J.M., Ford, M.L., Schlapschy, M., Kuhn, N., Lensch, A., Lifson, J., Nason, M., Skerra, A., Schreiber, G., Bosinger, S.E., and Douek, D.C., **Type I IFN signaling blockade by a PASylated antagonist during chronic SIV infection suppresses specific inflammatory pathways but does not alter T cell activation or virus replication.** *PLoS Pathog*, 2018.
51. Prodger, J.L., Lai, J., Reynolds, S.J., Keruly, J.C., Moore, R.D., Kasule, J., Kityamuweesi, T., Buule, P., Serwadda, D., Nason, M., Capoferri, A.A., Porcella, S.F., Siliciano, R.F., Redd, A.D., Siliciano, J.D., and Quinn, T.C., **Reduced Frequency of Cells Latently Infected With Replication-Competent Human Immunodeficiency Virus-1 in Virally Suppressed Individuals Living in Rakai, Uganda.** *Clin Infect Dis*, 2017.
52. Kennedy, S.B., Bolay, F., Kieh, M., Grandits, G., Badio, M., Ballou, R., Eckes, R., Feinberg, M., Follmann, D., Grund, B., Gupta, S., Hensley, L., Higgs, E., Janosko, K., Johnson, M., Kateh, F., Logue, J., Marchand, J., Monath, T., Nason, M., Nyenswah, T., Roman, F., Stavale, E., Wolfson, J., Neaton, J.D., Lane, H.C., and Group, P.I.S., **Phase 2 Placebo-Controlled Trial of Two Vaccines to Prevent Ebola in Liberia.** *N Engl J Med*, 2017.
53. Coates, E.E., Costner, P.J., Nason, M.C., Herrin, D.M., Conant, S., Herscovitch, P., Sarwar, U.N., Holman, L., Mitchell, J., Yamshchikov, G., Koup, R.A., Graham, B.S., Millo, C.M., Ledgerwood, J.E., and Team, V.R.C.S., **Lymph Node Activation by PET/CT Following Vaccination With Licensed Vaccines for Human Papillomaviruses.** *Clin Nucl Med*, 2017.
54. Lyke, K.E., Ishizuka, A.S., Berry, A.A., Chakravarty, S., DeZure, A., Enama, M.E., James, E.R., Billingsley, P.F., Gunasekera, A., Manoj, A., Li, M., Ruben, A.J., Li, T., Eappen, A.G., Stafford, R.E., Kc, N., Murshedkar, T., Mendoza, F.H., Gordon, I.J., Zephir, K.L., Holman, L.A., Plummer, S.H., Hendel, C.S., Novik, L., Costner, P.J., Saunders, J.G., Berkowitz, N.M., Flynn, B.J., Nason, M.C., Garver, L.S., Laurens, M.B., Plowe, C.V., Richie, T.L., Graham, B.S., Roederer, M., Sim, B.K., Ledgerwood, J.E., Hoffman, S.L., and Seder, R.A., **Attenuated PfSPZ Vaccine induces strain-transcending T cells and durable protection against heterologous controlled human malaria infection.** *Proc Natl Acad Sci U S A*, 2017.

55. Pettitt, J., Higgs, E., Fallah, M., Nason, M., Stavale, E., Marchand, J., Reilly, C., Jensen, K., Dighero-Kemp, B., Tuznik, K., Logue, J., Bolay, F., and Hensley, L., **Assessment and Optimization of the GeneXpert Diagnostic Platform for Detection of Ebola Virus RNA in Seminal Fluid.** *J Infect Dis*, 2017.
56. Higgs, E.S., Dubey, S.A., Collier, B.A.G., Simon, J.K., Bollinger, L., Sorenson, R.A., Wilson, B., Nason, M.C., and Hensley, L.E., **Accelerating Vaccine Development During the 2013-2016 West African Ebola Virus Disease Outbreak.** *Curr Top Microbiol Immunol*, 2017.
57. Nason, M., *Ebola Vaccine Trials.* , in *Marburg- and Ebolaviruses: From Ecosystems to Molecules.*, E. Mühlberger, Hensley, Lisa L., Towner, Jonathan S. , Editor. 2017, Springer.
58. Dowd, K.A., Ko, S.Y., Morabito, K.M., Yang, E.S., Pelc, R.S., DeMasco, C.R., Castilho, L.R., Abbink, P., Boyd, M., Nityanandam, R., Gordon, D.N., Gallagher, J.R., Chen, X., Todd, J.P., Tsybovsky, Y., Harris, A., Huang, Y.S., Higgs, S., Vanlandingham, D.L., Andersen, H., Lewis, M.G., De La Barrera, R., Eckels, K.H., Jarman, R.G., Nason, M.C., Barouch, D.H., Roederer, M., Kong, W.P., Mascola, J.R., Pierson, T.C., and Graham, B.S., **Rapid development of a DNA vaccine for Zika virus.** *Science*, 2016.
59. Gautam, R., Nishimura, Y., Pegu, A., Nason, M.C., Klein, F., Gazumyan, A., Golijanin, J., Buckler-White, A., Sadjadpour, R., Wang, K., Mankoff, Z., Schmidt, S.D., Lifson, J.D., Mascola, J.R., Nussenzweig, M.C., and Martin, M.A., **A single injection of anti-HIV-1 antibodies protects against repeated SHIV challenges.** *Nature*, 2016.
60. Nason, M.C., Patel, E.U., Kirkpatrick, A.R., Prodder, J.L., Shahabi, K., Tobian, A.A., Gianella, S., Kalibbala, S., Ssebowa, P., Kaul, R., Gray, R.H., Quinn, T.C., Serwadda, D., Reynolds, S.J., and Redd, A.D., **Immunological Signaling During Herpes Simplex Virus-2 and Cytomegalovirus Vaginal Shedding After Initiation of Antiretroviral Treatment.** *Open Forum Infect Dis*, 2016.
61. Ishizuka, A.S., Lyke, K.E., DeZure, A., Berry, A.A., Richie, T.L., Mendoza, F.H., Enama, M.E., Gordon, I.J., Chang, L.J., Sarwar, U.N., Zephir, K.L., Holman, L.A., James, E.R., Billingsley, P.F., Gunasekera, A., Chakravarty, S., Manoj, A., Li, M., Ruben, A.J., Li, T., Eappen, A.G., Stafford, R.E., K, C.N., Murshedkar, T., DeCederfelt, H., Plummer, S.H., Hendel, C.S., Novik, L., Costner, P.J., Saunders, J.G., Laurens, M.B., Plowe, C.V., Flynn, B., Whalen, W.R., Todd, J.P., Noor, J., Rao, S., Sierra-Davidson, K., Lynn, G.M., Epstein, J.E., Kemp, M.A., Fahle, G.A., Mikolajczak, S.A., Fishbaugher, M., Sack, B.K., Kappe, S.H., Davidson, S.A., Garver, L.S., Bjorkstrom, N.K., Nason, M.C., Graham, B.S., Roederer, M., Sim, B.K., Hoffman, S.L., Ledgerwood, J.E., Seder, R.A., Vrc, and Teams, V.R.C.S., **Corrigendum: Protection against malaria at 1 year and immune correlates following PfSPZ vaccination.** *Nat Med*, 2016.
62. Ishizuka, A.S., Lyke, K.E., DeZure, A., Berry, A.A., Richie, T.L., Mendoza, F.H., Enama, M.E., Gordon, I.J., Chang, L.J., Sarwar, U.N., Zephir, K.L., Holman, L.A., James, E.R., Billingsley, P.F., Gunasekera, A., Chakravarty, S., Manoj, A., Li, M., Ruben, A.J., Li, T., Eappen, A.G., Stafford, R.E., K, C.N., Murshedkar, T., DeCederfelt, H., Plummer, S.H., Hendel, C.S., Novik, L., Costner, P.J., Saunders, J.G., Laurens, M.B., Plowe, C.V., Flynn, B., Whalen, W.R., Todd, J.P., Noor, J., Rao, S., Sierra-Davidson, K., Lynn, G.M., Epstein, J.E., Kemp, M.A., Fahle, G.A., Mikolajczak, S.A., Fishbaugher, M., Sack, B.K., Kappe, S.H., Davidson, S.A., Garver, L.S., Bjorkstrom, N.K., Nason, M.C., Graham, B.S., Roederer, M., Sim, B.K., Hoffman, S.L., Ledgerwood, J.E., and Seder, R.A., **Protection against malaria at 1 year and immune correlates following PfSPZ vaccination.** *Nat Med*, 2016.
63. Bolton, D.L., Pegu, A., Wang, K., McGinnis, K., Nason, M., Foulds, K., Letukas, V., Schmidt, S.D., Chen, X., Todd, J.P., Lifson, J.D., Rao, S., Michael, N.L., Robb, M.L., Mascola, J.R., and Koup, R.A., **Human Immunodeficiency Virus Type 1 Monoclonal Antibodies Suppress Acute Simian-Human Immunodeficiency Virus Viremia and Limit Seeding of Cell-Associated Viral Reservoirs.** *J Virol*, 2016.
64. Kennedy, S.B., Neaton, J.D., Lane, H.C., Kieh, M.W., Massaquoi, M.B., Touchette, N.A., Nason, M.C., Follmann, D.A., Boley, F.K., Johnson, M.P., Larson, G., Kateh, F.N., and Nyenswah, T.G., **Implementation of an Ebola virus disease vaccine clinical trial during the Ebola epidemic in Liberia: Design, procedures, and challenges.** *Clin Trials*, 2016.
65. Nason, M., **Statistics and logistics: Design of Ebola vaccine trials in West Africa.** *Clin Trials*, 2016.

66. Crank, M.C., Wilson, E.M., Novik, L., Enama, M.E., Hendel, C.S., Gu, W., Nason, M.C., Bailer, R.T., Nabel, G.J., McDermott, A.B., Mascola, J.R., Koup, R.A., Ledgerwood, J.E., Graham, B.S., and Team, V.R.C.S., **Safety and Immunogenicity of a rAd35-EnvA Prototype HIV-1 Vaccine in Combination with rAd5-EnvA in Healthy Adults (VRC 012)**. *PLoS One*, 2016.
67. Laeyendecker, O., Redd, A.D., Nason, M., Longosz, A.F., Karim, Q.A., Naranbhai, V., Garrett, N., Eshleman, S.H., Abdool Karim, S.S., and Quinn, T.C., **Antibody Maturation in Women Who Acquire HIV Infection While Using Antiretroviral Preexposure Prophylaxis**. *J Infect Dis*, 2015.
68. Ngwuta, J.O., Chen, M., Modjarrad, K., Joyce, M.G., Kanekiyo, M., Kumar, A., Yassine, H.M., Moin, S.M., Killikelly, A.M., Chuang, G.Y., Druz, A., Georgiev, I.S., Rundlet, E.J., Sastry, M., Stewart-Jones, G.B., Yang, Y., Zhang, B., Nason, M.C., Capella, C., Peeples, M.E., Ledgerwood, J.E., McLellan, J.S., Kwong, P.D., and Graham, B.S., **Prefusion F-specific antibodies determine the magnitude of RSV neutralizing activity in human sera**. *Sci Transl Med*, 2015.
69. Siddiqui, S., Sarro, Y., Diarra, B., Diallo, H., Guindo, O., Dabita, D., Tall, M., Hammond, A., Kassambara, H., Goita, D., Dembele, P., Traore, B., Hengel, R., Nason, M., Warfield, J., Washington, J., Polis, M., Diallo, S., Dao, S., Koita, O., Lane, H.C., Catalfamo, M., and Tounkara, A., **Tuberculosis specific responses following therapy for TB: Impact of HIV co-infection**. *Clin Immunol*, 2015.
70. Huang, Y., Karuna, S.T., Janes, H., Frahm, N., Nason, M., Edlefsen, P.T., Kublin, J.G., Corey, L., McElrath, M.J., and Gilbert, P.B., **Use of placebos in Phase 1 preventive HIV vaccine clinical trials**. *Vaccine*, 2015.
71. Francica, J.R., Sheng, Z., Zhang, Z., Nishimura, Y., Shingai, M., Ramesh, A., Keele, B.F., Schmidt, S.D., Flynn, B.J., Darko, S., Lynch, R.M., Yamamoto, T., Matus-Nicodemus, R., Wolinsky, D., Program, N.C.S., Nason, M., Valiante, N.M., Malyala, P., De Gregorio, E., Barnett, S.W., Singh, M., O'Hagan, D.T., Koup, R.A., Mascola, J.R., Martin, M.A., Kepler, T.B., Douek, D.C., Shapiro, L., and Seder, R.A., **Analysis of immunoglobulin transcripts and hypermutation following SHIV(AD8) infection and protein-plus-adjuvant immunization**. *Nat Commun*, 2015.
72. Lynch, R.M., Wong, P., Tran, L., O'Dell, S., Nason, M.C., Li, Y., Wu, X., and Mascola, J.R., **HIV-1 fitness cost associated with escape from the VRC01 class of CD4 binding site neutralizing antibodies**. *J Virol*, 2015.
73. Huang, Y., Follmann, D., Nason, M., Zhang, L., Huang, Y., Mehrotra, D.V., Moodie, Z., Metch, B., Janes, H., Keefer, M.C., Churchyard, G., Robb, M.L., Fast, P.E., Duerr, A., McElrath, M.J., Corey, L., Mascola, J.R., Graham, B.S., Sobieszczyk, M.E., Kublin, J.G., Robertson, M., Hammer, S.M., Gray, G.E., Buchbinder, S.P., and Gilbert, P.B., **Effect of rAd5-Vector HIV-1 Preventive Vaccines on HIV-1 Acquisition: A Participant-Level Meta-Analysis of Randomized Trials**. *PLoS One*, 2015.
74. Shingai, M., Donau, O.K., Plishka, R.J., Buckler-White, A., Mascola, J.R., Nabel, G.J., Nason, M.C., Montefiori, D., Moldt, B., Poignard, P., Diskin, R., Bjorkman, P.J., Eckhaus, M.A., Klein, F., Mouquet, H., Cetrulo Lorenzi, J.C., Gazumyan, A., Burton, D.R., Nussenzweig, M.C., Martin, M.A., and Nishimura, Y., **Passive transfer of modest titers of potent and broadly neutralizing anti-HIV monoclonal antibodies block SHIV infection in macaques**. *J Exp Med*, 2014.
75. Ko, S.Y., Pegu, A., Rudicell, R.S., Yang, Z.Y., Joyce, M.G., Chen, X., Wang, K., Bao, S., Kraemer, T.D., Rath, T., Zeng, M., Schmidt, S.D., Todd, J.P., Penzak, S.R., Saunders, K.O., Nason, M.C., Haase, A.T., Rao, S.S., Blumberg, R.S., Mascola, J.R., and Nabel, G.J., **Enhanced neonatal Fc receptor function improves protection against primate SHIV infection**. *Nature*, 2014.
76. Rudicell, R.S., Kwon, Y.D., Ko, S.Y., Pegu, A., Louder, M.K., Georgiev, I.S., Wu, X., Zhu, J., Boyington, J.C., Chen, X., Shi, W., Yang, Z.Y., Doria-Rose, N.A., McKee, K., O'Dell, S., Schmidt, S.D., Chuang, G.Y., Druz, A., Soto, C., Yang, Y., Zhang, B., Zhou, T., Todd, J.P., Lloyd, K.E., Eudailey, J., Roberts, K.E., Donald, B.R., Bailer, R.T., Ledgerwood, J., Program, N.C.S., Mullikin, J.C., Shapiro, L., Koup, R.A., Graham, B.S., Nason, M.C., Connors, M., Haynes, B.F., Rao, S.S., Roederer, M., Kwong, P.D., Mascola, J.R., and Nabel, G.J., **Enhanced potency of a broadly neutralizing HIV-1 antibody in vitro improves protection against lentiviral infection in vivo**. *J Virol*, 2014.

77. Wentzensen, N., Nason, M., Schiffman, M., Dodd, L., Hunt, W.C., Wheeler, C.M., and New Mexico, H.P.V.P.R.S.C., **No evidence for synergy between human papillomavirus genotypes for the risk of high-grade squamous intraepithelial lesions in a large population-based study.** *J Infect Dis*, 2014.
78. Sandler, N.G., Bosinger, S.E., Estes, J.D., Zhu, R.T., Tharp, G.K., Boritz, E., Levin, D., Wijeyesinghe, S., Makamdop, K.N., del Prete, G.Q., Hill, B.J., Timmer, J.K., Reiss, E., Yarden, G., Darko, S., Contijoch, E., Todd, J.P., Silvestri, G., Nason, M., Norgren, R.B., Jr., Keele, B.F., Rao, S., Langer, J.A., Lifson, J.D., Schreiber, G., and Douek, D.C., **Type I interferon responses in rhesus macaques prevent SIV infection and slow disease progression.** *Nature*, 2014.
79. Pegu, A., Yang, Z.Y., Boyington, J.C., Wu, L., Ko, S.Y., Schmidt, S.D., McKee, K., Kong, W.P., Shi, W., Chen, X., Todd, J.P., Letvin, N.L., Huang, J., Nason, M.C., Hoxie, J.A., Kwong, P.D., Connors, M., Rao, S.S., Mascola, J.R., and Nabel, G.J., **Neutralizing antibodies to HIV-1 envelope protect more effectively in vivo than those to the CD4 receptor.** *Sci Transl Med*, 2014.
80. Roederer, M., Keele, B.F., Schmidt, S.D., Mason, R.D., Welles, H.C., Fischer, W., Labranche, C., Foulds, K.E., Louder, M.K., Yang, Z.Y., Todd, J.P., Buzby, A.P., Mach, L.V., Shen, L., Seaton, K.E., Ward, B.M., Bailer, R.T., Gottardo, R., Gu, W., Ferrari, G., Alam, S.M., Denny, T.N., Montefiori, D.C., Tomaras, G.D., Korber, B.T., Nason, M.C., Seder, R.A., Koup, R.A., Letvin, N.L., Rao, S.S., Nabel, G.J., and Mascola, J.R., **Immunological and virological mechanisms of vaccine-mediated protection against SIV and HIV.** *Nature*, 2014.
81. Sarwar, U.N., Novik, L., Enama, M.E., Plummer, S.A., Koup, R.A., Nason, M.C., Bailer, R.T., McDermott, A.B., Roederer, M., Mascola, J.R., Ledgerwood, J.E., Graham, B.S., and team, V.R.C.s., **Homologous boosting with adenoviral serotype 5 HIV vaccine (rAd5) vector can boost antibody responses despite preexisting vector-specific immunity in a randomized phase I clinical trial.** *PLoS One*, 2014.
82. Herrin, D.M., Coates, E.E., Costner, P.J., Kemp, T.J., Nason, M.C., Saharia, K.K., Pan, Y., Sarwar, U.N., Holman, L., Yamshchikov, G., Koup, R.A., Pang, Y.Y., Seder, R.A., Schiller, J.T., Graham, B.S., Pinto, L.A., and Ledgerwood, J.E., **Comparison of adaptive and innate immune responses induced by licensed vaccines for Human Papillomavirus.** *Hum Vaccin Immunother*, 2014.
83. Enama, M.E., Ledgerwood, J.E., Novik, L., Nason, M.C., Gordon, I.J., Holman, L., Bailer, R.T., Roederer, M., Koup, R.A., Mascola, J.R., Nabel, G.J., Graham, B.S., and Team, V.R.C.S., **Phase I randomized clinical trial of VRC DNA and rAd5 HIV-1 vaccine delivery by intramuscular (i.m.), subcutaneous (s.c.) and intradermal (i.d.) administration (VRC 011).** *PLoS One*, 2014.
84. Seder, R.A., Chang, L.J., Enama, M.E., Zephir, K.L., Sarwar, U.N., Gordon, I.J., Holman, L.A., James, E.R., Billingsley, P.F., Gunasekera, A., Richman, A., Chakravarty, S., Manoj, A., Velmurugan, S., Li, M., Ruben, A.J., Li, T., Eappen, A.G., Stafford, R.E., Plummer, S.H., Hendel, C.S., Novik, L., Costner, P.J., Mendoza, F.H., Saunders, J.G., Nason, M.C., Richardson, J.H., Murphy, J., Davidson, S.A., Richie, T.L., Sedegah, M., Sutamihardja, A., Fahle, G.A., Lyke, K.E., Laurens, M.B., Roederer, M., Tewari, K., Epstein, J.E., Sim, B.K., Ledgerwood, J.E., Graham, B.S., Hoffman, S.L., and Team, V.R.C.S., **Protection against malaria by intravenous immunization with a nonreplicating sporozoite vaccine.** *Science*, 2013.
85. Georgiev, I.S., Doria-Rose, N.A., Zhou, T., Kwon, Y.D., Staupe, R.P., Moquin, S., Chuang, G.Y., Louder, M.K., Schmidt, S.D., Altae-Tran, H.R., Bailer, R.T., McKee, K., Nason, M., O'Dell, S., Ofek, G., Pancera, M., Srivatsan, S., Shapiro, L., Connors, M., Migueles, S.A., Morris, L., Nishimura, Y., Martin, M.A., Mascola, J.R., and Kwong, P.D., **Delineating antibody recognition in polyclonal sera from patterns of HIV-1 isolate neutralization.** *Science*, 2013.
86. Mahnke, Y.D., Song, K., Sauer, M.M., Nason, M.C., Giret, M.T., Carvalho, K.I., Costa, P.R., Roederer, M., and Kallas, E.G., **Early immunologic and virologic predictors of clinical HIV-1 disease progression.** *AIDS*, 2013.
87. Casazza, J.P., Bowman, K.A., Adzaku, S., Smith, E.C., Enama, M.E., Bailer, R.T., Price, D.A., Gostick, E., Gordon, I.J., Ambrozak, D.R., Nason, M.C., Roederer, M., Andrews, C.A., Maldarelli, F.M., Wiegand, A., Kearney, M.F., Persaud, D., Ziemiak, C., Gottardo, R., Ledgerwood, J.E., Graham, B.S., Koup, R.A., and Team, V.R.C.S.,

Therapeutic vaccination expands and improves the function of the HIV-specific memory T-cell repertoire. *J Infect Dis*, 2013.

88. Graham, B.S., Enama, M.E., Nason, M.C., Gordon, I.J., Peel, S.A., Ledgerwood, J.E., Plummer, S.A., Mascola, J.R., Bailer, R.T., Roederer, M., Koup, R.A., Nabel, G.J., and Team, V.R.C.S., **DNA vaccine delivered by a needle-free injection device improves potency of priming for antibody and CD8+ T-cell responses after rAd5 boost in a randomized clinical trial.** *PLoS One*, 2013.
89. Yamamoto, T., Johnson, M.J., Price, D.A., Wolinsky, D.I., Almeida, J.R., Petrovas, C., Nason, M., Yeh, W.W., Shen, L., Roederer, M., Rao, S.S., McDermott, A.B., Lefebvre, F., Nabel, G.J., Haddad, E.K., Letvin, N.L., Douek, D.C., and Koup, R.A., **Virus inhibition activity of effector memory CD8(+) T cells determines simian immunodeficiency virus load in vaccinated monkeys after vaccine breakthrough infection.** *J Virol*, 2012.
90. Doria-Rose, N.A., Louder, M.K., Yang, Z., O'Dell, S., Nason, M., Schmidt, S.D., McKee, K., Seaman, M.S., Bailer, R.T., and Mascola, J.R., **HIV-1 neutralization coverage is improved by combining monoclonal antibodies that target independent epitopes.** *J Virol*, 2012.
91. Cheng, C., Wang, L., Gall, J.G., Nason, M., Schwartz, R.M., McElrath, M.J., DeRosa, S.C., Hural, J., Corey, L., Buchbinder, S.P., and Nabel, G.J., **Decreased pre-existing Ad5 capsid and Ad35 neutralizing antibodies increase HIV-1 infection risk in the Step trial independent of vaccination.** *PLoS One*, 2012.
92. Follmann, D. and Nason, M., **An augmented probit model for missing predictable covariates in quantal bioassay with small sample size.** *Biometrics*, 2011.
93. Ledgerwood, J.E., Pierson, T.C., Hubka, S.A., Desai, N., Rucker, S., Gordon, I.J., Enama, M.E., Nelson, S., Nason, M., Gu, W., Bundrant, N., Koup, R.A., Bailer, R.T., Mascola, J.R., Nabel, G.J., Graham, B.S., and Team, V.R.C.S., **A West Nile virus DNA vaccine utilizing a modified promoter induces neutralizing antibody in younger and older healthy adults in a phase I clinical trial.** *J Infect Dis*, 2011.
94. Yamamoto, T., Price, D.A., Casazza, J.P., Ferrari, G., Nason, M., Chattopadhyay, P.K., Roederer, M., Gostick, E., Katsikis, P.D., Douek, D.C., Haubrich, R., Petrovas, C., and Koup, R.A., **Surface expression patterns of negative regulatory molecules identify determinants of virus-specific CD8+ T-cell exhaustion in HIV infection.** *Blood*, 2011.
95. Sandler, N.G., Wand, H., Roque, A., Law, M., Nason, M.C., Nixon, D.E., Pedersen, C., Ruxrungtham, K., Lewin, S.R., Emery, S., Neaton, J.D., Brenchley, J.M., Deeks, S.G., Sereti, I., Douek, D.C., and Group, I.S.S., **Plasma levels of soluble CD14 independently predict mortality in HIV infection.** *J Infect Dis*, 2011.
96. Nason, M.W., Jr., Adhikari, A., Bozinoski, M., Gordon, J.A., and Role, L.W., **Disrupted activity in the hippocampal-accumbens circuit of type III neuregulin 1 mutant mice.** *Neuropsychopharmacology*, 2011.
97. Roederer, M., Nozzi, J.L., and Nason, M.C., **SPICE: exploration and analysis of post-cytometric complex multivariate datasets.** *Cytometry A*, 2011.
98. Nason, M. and Follmann, D., **Design and analysis of crossover trials for absorbing binary endpoints.** *Biometrics*, 2010.
99. Chen, M., Chang, J.S., Nason, M., Rangel, D., Gall, J.G., Graham, B.S., and Ledgerwood, J.E., **A flow cytometry-based assay to assess RSV-specific neutralizing antibody is reproducible, efficient and accurate.** *J Immunol Methods*, 2010.
100. Hersperger, A.R., Pereyra, F., Nason, M., Demers, K., Sheth, P., Shin, L.Y., Kovacs, C.M., Rodriguez, B., Sieg, S.F., Teixeira-Johnson, L., Gudonis, D., Goepfert, P.A., Lederman, M.M., Frank, I., Makedonas, G., Kaul, R., Walker, B.D., and Betts, M.R., **Perforin expression directly ex vivo by HIV-specific CD8 T-cells is a correlate of HIV elite control.** *PLoS Pathog*, 2010.

101. Rao, S.S., Kong, W.P., Wei, C.J., Van Hoeven, N., Gorres, J.P., Nason, M., Andersen, H., Tumpey, T.M., and Nabel, G.J., **Comparative efficacy of hemagglutinin, nucleoprotein, and matrix 2 protein gene-based vaccination against H5N1 influenza in mouse and ferret.** *PLoS One*, 2010.
102. Willey, R., Nason, M.C., Nishimura, Y., Follmann, D.A., and Martin, M.A., **Neutralizing antibody titers conferring protection to macaques from a simian/human immunodeficiency virus challenge using the TZM-bl assay.** *AIDS Res Hum Retroviruses*, 2010.
103. Cheng, C., Gall, J.G., Nason, M., King, C.R., Koup, R.A., Roederer, M., McElrath, M.J., Morgan, C.A., Churchyard, G., Baden, L.R., Duerr, A.C., Keefer, M.C., Graham, B.S., and Nabel, G.J., **Differential specificity and immunogenicity of adenovirus type 5 neutralizing antibodies elicited by natural infection or immunization.** *J Virol*, 2010.
104. Koup, R.A., Roederer, M., Lamoreaux, L., Fischer, J., Novik, L., Nason, M.C., Larkin, B.D., Enama, M.E., Ledgerwood, J.E., Bailer, R.T., Mascola, J.R., Nabel, G.J., Graham, B.S., Team, V.R.C.S., and Team, V.R.C.S., **Priming immunization with DNA augments immunogenicity of recombinant adenoviral vectors for both HIV-1 specific antibody and T-cell responses.** *PLoS One*, 2010.
105. Doria-Rose, N.A., Klein, R.M., Daniels, M.G., O'Dell, S., Nason, M., Lapedes, A., Bhattacharya, T., Migueles, S.A., Wyatt, R.T., Korber, B.T., Mascola, J.R., and Connors, M., **Breadth of human immunodeficiency virus-specific neutralizing activity in sera: clustering analysis and association with clinical variables.** *J Virol*, 2010.
106. Wu, X., Yang, Z.Y., Li, Y., Hogerkorp, C.M., Schief, W.R., Seaman, M.S., Zhou, T., Schmidt, S.D., Wu, L., Xu, L., Longo, N.S., McKee, K., O'Dell, S., Louder, M.K., Wycuff, D.L., Feng, Y., Nason, M., Doria-Rose, N., Connors, M., Kwong, P.D., Roederer, M., Wyatt, R.T., Nabel, G.J., and Mascola, J.R., **Rational design of envelope identifies broadly neutralizing human monoclonal antibodies to HIV-1.** *Science*, 2010.
107. Proschan, M.A. and Nason, M., **Conditioning in 2 x 2 tables.** *Biometrics*, 2009.
108. Doria-Rose, N.A., Klein, R.M., Manion, M.M., O'Dell, S., Phogat, A., Chakrabarti, B., Hallahan, C.W., Migueles, S.A., Wrammert, J., Ahmed, R., Nason, M., Wyatt, R.T., Mascola, J.R., and Connors, M., **Frequency and phenotype of human immunodeficiency virus envelope-specific B cells from patients with broadly cross-neutralizing antibodies.** *J Virol*, 2009.
109. Price, D.A., Asher, T.E., Wilson, N.A., Nason, M.C., Brenchley, J.M., Metzler, I.S., Venturi, V., Gostick, E., Chattopadhyay, P.K., Roederer, M., Davenport, M.P., Watkins, D.I., and Douek, D.C., **Public clonotype usage identifies protective Gag-specific CD8+ T cell responses in SIV infection.** *J Exp Med*, 2009.
110. Ruckwardt, T.J., Bonaparte, K.L., Nason, M.C., and Graham, B.S., **Regulatory T cells promote early influx of CD8+ T cells in the lungs of respiratory syncytial virus-infected mice and diminish immunodominance disparities.** *J Virol*, 2009.
111. Wu, X., Sambor, A., Nason, M.C., Yang, Z.Y., Wu, L., Zolla-Pazner, S., Nabel, G.J., and Mascola, J.R., **Soluble CD4 broadens neutralization of V3-directed monoclonal antibodies and guinea pig vaccine sera against HIV-1 subtype B and C reference viruses.** *Virology*, 2008.
112. Martin, J.E., Louder, M.K., Holman, L.A., Gordon, I.J., Enama, M.E., Larkin, B.D., Andrews, C.A., Vogel, L., Koup, R.A., Roederer, M., Bailer, R.T., Gomez, P.L., Nason, M., Mascola, J.R., Nabel, G.J., Graham, B.S., and Team, V.R.C.S., **A SARS DNA vaccine induces neutralizing antibody and cellular immune responses in healthy adults in a Phase I clinical trial.** *Vaccine*, 2008.
113. Sheets, R.L., Stein, J., Bailer, R.T., Koup, R.A., Andrews, C., Nason, M., He, B., Koo, E., Trotter, H., Duffy, C., Manetz, T.S., and Gomez, P., **Biodistribution and toxicological safety of adenovirus type 5 and type 35 vectored vaccines against human immunodeficiency virus-1 (HIV-1), Ebola, or Marburg are similar despite differing adenovirus serotype vector, manufacturer's construct, or gene inserts.** *J Immunotoxicol*, 2008.

114. Rao, S., Kong, W.P., Wei, C.J., Yang, Z.Y., Nason, M., Styles, D., DeTolla, L.J., Panda, A., Sorrell, E.M., Song, H., Wan, H., Ramirez-Nieto, G.C., Perez, D., and Nabel, G.J., **Multivalent HA DNA vaccination protects against highly pathogenic H5N1 avian influenza infection in chickens and mice.** *PLoS One*, 2008.
115. Elloumi, F. and Nason, M., **SEARCHPATTOOL: a new method for mining the most specific frequent patterns for binding sites with application to prokaryotic DNA sequences.** *BMC Bioinformatics*, 2007.
116. Catanzaro, A.T., Roederer, M., Koup, R.A., Bailer, R.T., Enama, M.E., Nason, M.C., Martin, J.E., Rucker, S., Andrews, C.A., Gomez, P.L., Mascola, J.R., Nabel, G.J., Graham, B.S., and Team, V.R.C.S., **Phase I clinical evaluation of a six-plasmid multiclade HIV-1 DNA candidate vaccine.** *Vaccine*, 2007.
117. Seggewiss, R., Lore, K., Guenaga, F.J., Pittaluga, S., Mattapallil, J., Chow, C.K., Koup, R.A., Camphausen, K., Nason, M.C., Meier-Schellersheim, M., Donahue, R.E., Blazar, B.R., Dunbar, C.E., and Douek, D.C., **Keratinocyte growth factor augments immune reconstitution after autologous hematopoietic progenitor cell transplantation in rhesus macaques.** *Blood*, 2007.
118. Martin, J.E., Pierson, T.C., Hubka, S., Rucker, S., Gordon, I.J., Enama, M.E., Andrews, C.A., Xu, Q., Davis, B.S., Nason, M., Fay, M., Koup, R.A., Roederer, M., Bailer, R.T., Gomez, P.L., Mascola, J.R., Chang, G.J., Nabel, G.J., and Graham, B.S., **A West Nile virus DNA vaccine induces neutralizing antibody in healthy adults during a phase 1 clinical trial.** *J Infect Dis*, 2007.
119. Nason, M.A., Farrar, J., and Bartlett, D., **Strobilurin fungicides induce changes in photosynthetic gas exchange that do not improve water use efficiency of plants grown under conditions of water stress.** *Pest Manag Sci*, 2007.
120. Geldmacher, C., Gray, C., Nason, M., Currier, J.R., Haule, A., Njovu, L., Geis, S., Hoffmann, O., Maboko, L., Meyerhans, A., Cox, J., and Hoelscher, M., **A high viral burden predicts the loss of CD8 T-cell responses specific for subdominant gag epitopes during chronic human immunodeficiency virus infection.** *J Virol*, 2007.
121. Betts, M.R., Nason, M.C., West, S.M., De Rosa, S.C., Migueles, S.A., Abraham, J., Lederman, M.M., Benito, J.M., Goepfert, P.A., Connors, M., Roederer, M., and Koup, R.A., **HIV nonprogressors preferentially maintain highly functional HIV-specific CD8+ T cells.** *Blood*, 2006.
122. Sheets, R.L., Stein, J., Manetz, T.S., Duffy, C., Nason, M., Andrews, C., Kong, W.P., Nabel, G.J., and Gomez, P.L., **Biodistribution of DNA plasmid vaccines against HIV-1, Ebola, Severe Acute Respiratory Syndrome, or West Nile virus is similar, without integration, despite differing plasmid backbones or gene inserts.** *Toxicol Sci*, 2006.
123. Read, S.W., Higgins, J., Metcalf, J.A., Stevens, R.A., Rupert, A., Nason, M.C., Lane, H.C., and Sereti, I., **Decreased CD127 expression on T Cells in HIV-1-infected adults receiving antiretroviral therapy with or without intermittent IL-2 therapy.** *J Acquir Immune Defic Syndr*, 2006.
124. Nason, M., **Patterns of immune response to a vaccine or virus as measured by intracellular cytokine staining in flow cytometry: hypothesis generation and comparison of groups.** *J Biopharm Stat*, 2006.
125. Higgins, J., Metcalf, J.A., Stevens, R.A., Baseler, M., Nason, M.C., Lane, H.C., and Sereti, I., **Effects of lymphocyte isolation and timing of processing on detection of CD127 expression on T cells in human immunodeficiency virus-infected patients.** *Clin Diagn Lab Immunol*, 2005.
126. Nason, M., Emerson, S., and LeBlanc, M., **CARTScans: A Tool for Visualizing Complex Models.** *Journal of Computational and Graphical Statistics*, 2004.
127. Madigan, D.a.N., M., *Sampling Techniques & Statistics Perspectives on Data and Knowledge*, in *Handbook of Knowledge Discovery and Data Mining*. 2003, Oxford University Press.

128. Madigan, D., Raghavan, N., DuMouchel, W., Nason, M., Posse, C., and Ridgeway, G. , **Likelihood-based data squashing: A modeling approach to instance construction.** *Journal of Data Mining and Knowledge Discovery*, 2001.
129. Schaffner, A.M., D.; Hunt, E.; Graf, E.; Minstrell, J.; and Nason, M., *Benchmark Lessons and the World Wide Web: Tools for Teaching Statistics*, in *Proceedings of ICLS 96*, D.E.a.E. Domeshek, Editor. 1996, Association for the Advancement of Computing in Education.